Recombinant human DNase in conditions other than cystic fibrosis;Rekombinant humant deoxyribonuklease til andet end cystisk fibrose

Ugeskrift for Laeger

Volumn 172, Issue 8, 2010, Pages

  Kristensen, Kim ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBONUCLEASE I; DNASE1 PROTEIN, HUMAN;

ADULT; ASTHMA; ATELECTASIS; BRONCHIECTASIS; CHILD; CILIARY DYSKINESIA; DRUG CONTRAINDICATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; KARTAGENER SYNDROME; POSTOPERATIVE COMPLICATION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT DISEASE; REVIEW; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADULT; ASTHMA; BRONCHIECTASIS; CHILD; CILIARY MOTILITY DISORDERS; DEOXYRIBONUCLEASE I; HUMANS; KARTAGENER SYNDROME; POSTOPERATIVE COMPLICATIONS; PULMONARY ATELECTASIS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY TRACT DISEASES; TREATMENT OUTCOME;

EID: 77954932163     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Voynow JA, Rubin BK. Mucins, mucus, and sputum. Chest 2009;135:505-12.
2. Matthews LW, Spector S, Lemm J et al. Studies on pulmonary secretions. I. The over-all chemical composition of pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy. Am Rev Respir Dis 1963;88:199-204.
3. Picot R, Das I, Reid L. Pus, deoxyribonucleic acid, and sputum viscosity. Thorax 1978;33:235-42.
4. Elmes PC, White JC. Deoxyribonuclease in the treatment of purulent bronchitis. Thorax 1953;8:295-300.
5. Salomon A, Herchfus JA, Segal MS. Aerosols of pancreatic dornase in bronchopulmonary disease. Ann Allergy 1954;12:71-7.
6. Spier R, Witebsky E, Paine JR. Aerosolized pancreatic dornase and antibiotics in pulmonary infections: use in patients with postoperative and nonoperative infections. JAMA 1961;178:878-86.
7. Raskin P. Bronchospasm after inhalation of pancreatic dornase. Am Rev Respir Dis 1968;98:697-8.
8. Shak S, Capon DJ, Hellmiss R et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A 1990;87:9188-92.
9. Fuchs HJ, Borowitz DS, Christiansen DH et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331:637-42.
10. Riethmueller J, Borth-Bruhns T, Kumpf M et al. Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children. Pediatr Pulmonol 2006;41:61-6.
11. Boogaard R, Smit F, Schornagel R et al. Recombinant human deoxyribonuclease for the treatment of acute asthma in children. Thorax 2008;63:141-6.
12. Nasr SZ, Strouse PJ, Soskolne E et al. Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis. Chest 2001;120:203-8.
13. Boogaard R, Hulsmann AR, van Veen L et al. Recombinant human deoxyribonuclease in infants with respiratory syncytial virus bronchiolitis. Chest 2007;131:788-95.
14. Wills PJ, Wodehouse T, Corkery K et al. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability. Am J Respir Crit Care Med 1996;154(2 Pt 1):413-7.
15. O'Donnell AE, Barker AF, Ilowite JS et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998;113:1329-34.
16. El Hassan NO, Chess PR, Huysman MW et al. Rescue use of DNase in critical lung atelectasis and mucus retention in premature neonates. Pediatrics 2001;108:468-70.
17. Erdeve O, Uras N, Atasay B et al. Efficacy and safety of nebulized recombinant human DNase as rescue treatment for persistent atelectasis in newborns: case-series. Croat Med J 2007;48:234-9.
18. Voelker KG, Chetty KG, Mahutte CK. Resolution of recurrent atelectasis in spinal cord injury patients with administration of recombinant human DNase. Intensive Care Med 1996;22:582-4.
19. Boeuf B, Prouix F, Morneau S et al. Safety of endotracheal rh DNAse (Pulmozyme) for treatment of pulmonary atelectasis in mechanically ventilated children. Pediatr Pulmonol 1998;26:147.
20. Hendriks T, de HM, Lequin MH et al. DNase and atelectasis in non-cystic fibrosis pediatric patients. Crit Care 2005;9:R351-R356.
21. Desai M, Weller PH, Spencer DA. Clinical benefit from nebulized human recombinant DNase in Kartagener's syndrome. Pediatr Pulmonol 1995;20:307-8.
22. El-Abiad NM, Clifton S, Nasr SZ. Long-term use of nebulized human recombinant DNase1 in two siblings with primary ciliary dyskinesia. Respir Med 2007;101:2224-6.
23. Ten Berge M, Brinkhorst G, Kroon AA et al. DNase treatment in primary ciliary dyskinesia - assessment by nocturnal pulse oximetry. Pediatr Pulmonol 1999;27:59-61.
24. Fahy JV, Kim KW, Liu J et al. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 1995;95:843-52.
25. Wohl ME. Bronchiolitis. I: Chernick V, Boat T, Kendig E, eds. Kendig's disorders of the respiratory tract in children. Philadelphia: WB Saunders Company, 1998;473-85.